ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.
Overview
- Cancer Genome and Epigenetics Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Pediatrics, Emory University,Atlanta, Georgia, USA
- Department of Pathology, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Stem Cell Institute, UC San Diego, La Jolla, California, USA
- Chimerix (a Jazz Pharmaceuticals Company), Durham, North Carolina, USA
- Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA
- Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
Abstract
Background: Medulloblastoma (MB) is the most common malignant pediatric brain tumor, and has an urgent need for novel treatment approaches. Dordaviprone (ONC201) and its chemical derivative with nanomolar potency, ONC206, induce apoptosis of cancer cells by activation of the mitochondrial caseinolytic protease P (ClpP). Dordaviprone is currently in phase I clinical trials for pediatric patients with primary brain tumors.
Methods: In this study, we evaluated the preclinical therapeutic effects of ONC206 in MB and investigated its mechanism of action.
Results: We found evidence for high expression of ClpP at both the RNA and protein level in MB tumors, compared to very low expression in normal brain tissue. In addition, we saw a pronounced reduction in cell viability of human group 3 and group 4 and murine Sonic-Hedgehog-activated
Conclusion: Our results highlight ONC206 as a novel therapeutic option for patients with high-risk MB and provide strong rationale for testing the efficacy of ONC206 in the treatment of these patients.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE85217, at NCBI GEO; found in the text, “Molecular Data Mining”
Data Availability
All data that support the findings of the study are available from the corresponding author upon request.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 15 authors, 5 keywords, 16 MeSH terms, 14 funders, 43 references, 1 integrity notice.
Cite
This paper
Tzaridis, T., Liu, J., Chien, F. L., Malhotra, A., Zhu, D., Gershon, I., Zhang, H., Velazquez Vega, J. E., Schniederjan, M., Sposito, T., Adams, P. D., Allen, J. E., Prabhu, V. V., Wechsler-Reya, R. J., & MacDonald, T. J. (2026). ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma. Neuro-oncology, 28(7), 1753-1768. https://
BibTeX
@article{tzaridis2026onc
author = {Tzaridis, Theophilos and Liu, Jingbo and Chien, Franklin Lee and Malhotra, Anshu and Zhu, Dan and Gershon, Isabella and Zhang, Hongying and Velazquez Vega, Jose E and Schniederjan, Matthew and Sposito, Teresa and Adams, Peter D and Allen, Joshua E and Prabhu, Varun V and Wechsler-Reya, Robert J and MacDonald, Tobey J},
title = {{ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma}},
journal = {Neuro-oncology},
year = {2026},
month = jul,
volume = {28},
number = {7},
pages = {1753--1768},
publisher = {Oxford University Press},
issn = {1522-8517},
doi = {10.1093/
url = {https://
pmid = {41818696},
pmcid = {PMC13338324}
}
RIS
TY - JOUR
AU - Tzaridis, Theophilos
AU - Liu, Jingbo
AU - Chien, Franklin Lee
AU - Malhotra, Anshu
AU - Zhu, Dan
AU - Gershon, Isabella
AU - Zhang, Hongying
AU - Velazquez Vega, Jose E
AU - Schniederjan, Matthew
AU - Sposito, Teresa
AU - Adams, Peter D
AU - Allen, Joshua E
AU - Prabhu, Varun V
AU - Wechsler-Reya, Robert J
AU - MacDonald, Tobey J
TI - ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma
T2 - Neuro-oncology
J2 - Neuro Oncol
PY - 2026
DA - 2026/
VL - 28
IS - 7
SP - 1753
EP - 1768
SN - 1522-8517
PB - Oxford University Press
DO - 10.1093/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1093/
"type": "article-journal",
"title": "ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma",
"container-title": "Neuro-oncology",
"author": [
{
"family": "Tzaridis",
"given": "Theophilos"
},
{
"family": "Liu",
"given": "Jingbo"
},
{
"family": "Chien",
"given": "Franklin Lee"
},
{
"family": "Malhotra",
"given": "Anshu"
},
{
"family": "Zhu",
"given": "Dan"
},
{
"family": "Gershon",
"given": "Isabella"
},
{
"family": "Zhang",
"given": "Hongying"
},
{
"family": "Velazquez Vega",
"given": "Jose E"
},
{
"family": "Schniederjan",
"given": "Matthew"
},
{
"family": "Sposito",
"given": "Teresa"
},
{
"family": "Adams",
"given": "Peter D"
},
{
"family": "Allen",
"given": "Joshua E"
},
{
"family": "Prabhu",
"given": "Varun V"
},
{
"family": "Wechsler-Reya",
"given": "Robert J"
},
{
"family": "MacDonald",
"given": "Tobey J"
}
],
"container-title-short":
"volume": "28",
"issue": "7",
"page": "1753-1768",
"DOI": "10.1093/
"PMID": "41818696",
"PMCID": "PMC13338324",
"ISSN": "1522-8517",
"publisher": "Oxford University Press",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
1
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41467-022-35118-3 [code]
- Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.Journal: Nature communicationsIn common: other condition, mouse, 2 references, author Robert J Wechsler-Reya
- [2] doi:10.1038/s41419-023-06275-0
- The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment.Journal: Cell death & diseaseIn common: NCBI GEO GSE85217, other condition, 2 references
- [3] doi:10.1038/s42003-022-03654-9
- Combined MEK and JAK/
STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Journal: Communications biologyIn common: other condition, mouse, 2 references, author Robert J Wechsler-Reya - [4] doi:10.3390/cells14020072
- Modulation of Stemness and Differentiation Regulators by Valproic Acid in Medulloblastoma Neurospheres.Journal: CellsIn common: NCBI GEO GSE85217, other condition, 2 references
- [5] doi:10.1016/j.heliyon.2024.e34474
- Identification of a prognosis-related phagocytosis regulator gene signature in medulloblastoma.Journal: HeliyonIn common: NCBI GEO GSE85217, other condition, 2 references
- [6] doi:10.1158/0008-5472.can-22-2108
- Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.Journal: Cancer researchIn common: other condition, mouse, 1 reference, author Robert J Wechsler-Reya
- [7] doi:10.1038/s41698-024-00792-7 [code]
- In-depth inference of transcriptional regulatory networks reveals NPM1 as a therapeutic ribosomal regulator in MYC-amplified medulloblastoma.Journal: NPJ precision oncologyIn common: NCBI GEO GSE85217, other condition, 2 references
- [8] doi:10.1038/s41598-025-00763-3
- Medulloblastoma's master regulators and their association with patients' risk.Journal: Scientific reportsIn common: NCBI GEO GSE85217, other condition, 2 references
- [9] doi:10.1186/s40478-023-01557-2
- IGFBP2 promotes proliferation and cell migration through STAT3 signaling in Sonic hedgehog medulloblastoma.Journal: Acta neuropathologica communicationsIn common: NCBI GEO GSE85217, other condition, mouse, 1 reference
- [10] doi:10.1002/advs.202517834
- Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)In common: other condition, mouse, author Tobey J MacDonald
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
